At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 160 enrolled
Drug / intervention
Anti-GM-CSF Monoclonal Antibody 400mg +1 morebiological
Likely dose
Anti-GM-CSF Monoclonal Antibody 400mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Double-blind, Placebo-controlled, Randomized Study to Evaluate the Safety, Tolerability, and Efficacy of KB003 in Subjects With Asthma Inadequately Controlled by Corticosteroids
In Brief
A Phase 2 clinical trial evaluating Anti-GM-CSF Monoclonal Antibody 400mg and Placebo for Moderate-to-Severe Asthma. Completed, enrolled 160 participants across 70 sites in 6 countries.
Detailed Summary
This study will evaluate the safety, tolerability and efficacy of a single dose level of KB003 in subjects with inadequately controlled asthma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsModerate-to-Severe Asthma
CountriesAustralia, France, Poland, Ukraine, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedMay 2012
Enrollment StartJul 2012
Primary CompletionJul 2013
Study CompletionJan 2014
TodayJul 2026
First PostedMay 22, 2012
Enrollment StartJul 1, 2012
Primary CompletionJul 1, 2013
Study CompletionJan 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 14.1 years ago
Interventions
Anti-GM-CSF Monoclonal Antibody 400mgbiological
Anti-GM-CSF Monoclonal Antibody 400mg
Placeboother
Normal Saline